DIN 02526182 — RYBREVANT 350 MG
RYBREVANT is a solution of Amivantamab marketed by JANSSEN INC. The full Amivantamab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02526182
- Brand name
- RYBREVANT
- Active ingredient
- Amivantamab
- Strength
- 350 MG
- Dosage form
- SOLUTION
- Route
- INTRAVENOUS
- Manufacturer
- JANSSEN INC
- Health Canada status
- MARKETED
- Drug class
- Bispecific monoclonal antibody (EGFR/MET-directed antineoplastic)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Amivantamab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02569140 | RYBREVANT SC | 1600 MG | SOLUTION | JANSSEN INC | MARKETED |
| 02569159 | RYBREVANT SC | 2240 MG | SOLUTION | JANSSEN INC | MARKETED |
| 02569167 | RYBREVANT SC | 2400 MG | SOLUTION | JANSSEN INC | MARKETED |
| 02569175 | RYBREVANT SC | 3520 MG | SOLUTION | JANSSEN INC | MARKETED |